FDA Unveils Major Reforms to Speed Up and Cut Costs in Biosimilar Drug Development
The U.S. Food and Drug Administration (FDA) has introduced significant reforms aimed at making the development of biosimilar medicines, lower-cost “generic” alternatives to biologic drugs, faster, simpler, and more affordable.
In its newly released draft guidance, the agency proposed updates to streamline biosimilarity studies and eliminate unnecessary clinical testing, reducing both time and expense for developers.
Additionally, the FDA announced a new initiative to help biosimilars qualify more easily as interchangeable with brand-name biologics, enabling patients and pharmacists to access safe, effective, and lower-cost treatment options with greater ease.
Biologic Drugs’ High Cost Burden
It also noted that the expensive biologic drugs account for only 5 per cent of prescriptions in the U.S. but make up 51 per cent of total drug spending as of 2024.
Although FDA-approved biosimilars are as safe and effective as branded biologics, their market share remains below 20 per cent.
So far, the FDA has approved 76 biosimilars, which is only a small fraction compared to more than 30,000 approved generic drugs. Notably, only about 10 per cent of biologic drugs expected to lose patent protection in the next decade currently have a biosimilar in development.
Government Leaders Back the Reform
Health and Human Services Secretary Robert F. Kennedy Jr. said, “Today’s announcement of biosimilar reform furthers President Trump’s directive to lower drug prices for the American people. This bold action by the FDA accelerates biosimilar development, drives market competition, expands patient options, and advances our mission to Make America Healthy Again.”
FDA Commissioner Marty Makary, M.D., M.P.H., added that biosimilars could significantly reduce healthcare costs. “By streamlining the biosimilar development process and helping advance interchangeability, we can achieve massive cost reductions for advanced treatments for cancer, autoimmune diseases, and rare disorders affecting millions of Americans,” he said.
Details of the FDA’s Updated Draft Guidance
The FDA’s new draft guidance, “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies,” is based on data and experience since the first biosimilar approval in 2015.
Comparative efficacy studies, which take one to three years and cost about USD 24 million on average, have shown low sensitivity compared to other analytical assessments. The updated guidance now allows developers to rely more on analytical testing instead of human clinical studies.
Reduction In Testing And Development Costs
Additionally, the FDA will generally no longer recommend “switching studies” that were previously required for interchangeable biosimilars but not for generic drugs. These changes are expected to reduce development time, costs, and confusion among patients.
The biosimilar approval pathway was created in 2010 under the Biologics Price Competition and Innovation Act to promote competition in markets dominated by high-cost biologics.
Disclaimer: This is a syndicated news article with inputs from ANI. The content has been mildly edited for style and clarity while preserving the original facts and context.
Also Read: Trump-Putin Summit Cancelled After Tense Call Over Russia’s Demands…
Aishwarya is a journalism graduate with over three years of experience thriving in the buzzing corporate media world. She’s got a knack for decoding business news, tracking the twists and turns of the stock market, covering the masala of the entertainment world, and sometimes her stories come with just the right sprinkle of political commentary. She has worked with several organizations, interned at ZEE and gained professional skills at TV9 and News24, And now is learning and writing at NewsX, she’s no stranger to the newsroom hustle. Her storytelling style is fast-paced, creative, and perfectly tailored to connect with both the platform and its audience. Moto: Approaching every story from the reader’s point of view, backing up her insights with solid facts.
Always bold with her opinions, she also never misses the chance to weave in expert voices, keeping things balanced and insightful. In short, Aishwarya brings a fresh, sharp, and fact-driven voice to every story she touches.
